Clinical experience with donepezil (Aricept™) in the UK
Experience of the use of Donepezil (Aricept™) in the UK since licencing is discussed. The results of a 30 week double blind parallel group study in the US of Donepezil 5 or 10mg versus placebo show statistically significant improvements in cognitive and clinical global assessments. Beneficial effects were demonstrated in the absence of significant adverse effects on physical or laboratory values. The guidelines for use adopted in the UK are discussed with the emphasis on identifying non-cognitive behaviours, as significant improvements in these have been found and often have more impact on quality of life than cognitive improvements alone.
KeywordsDementia With Lewy Body Cognitive Improvement Dementia Sufferer Detailed Neuro Psychological Testing Clinical Global Assessment
Unable to display preview. Download preview PDF.
- EISAI Corp (1996) Data on file. Teaneck N J., U.S.A.Google Scholar
- Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psych 141/11: 1356–1364Google Scholar
- Wilcock G, Banergee A, Burns A, Chubb A, Jones R, Lawlor B, Rossor M, Sharp D, Wilkinson DG (1997) Setting standards in Alzheimer’s disease management in Primary and Secondary care. Geriatr Med 27 (part 3) [Suppl]Google Scholar
- World Health Organisation (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar